BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26077004)

  • 1. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
    Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
    Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
    Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
    BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
    Langevin SM; Christensen BC
    Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
    Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
    Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
    Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
    Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
    Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
    Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
    Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M
    Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
    Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
    Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between
    Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
    J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.